Trexquant Investment LP Boosts Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Trexquant Investment LP grew its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 25.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 49,297 shares of the specialty pharmaceutical company’s stock after buying an additional 10,090 shares during the period. Trexquant Investment LP owned 0.08% of Jazz Pharmaceuticals worth $6,071,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. IFP Advisors Inc acquired a new stake in Jazz Pharmaceuticals in the fourth quarter valued at approximately $25,000. CoreFirst Bank & Trust purchased a new position in Jazz Pharmaceuticals during the 4th quarter worth $28,000. Allianz SE acquired a new position in Jazz Pharmaceuticals during the 4th quarter valued at about $29,000. Jones Financial Companies Lllp boosted its holdings in Jazz Pharmaceuticals by 75.1% in the fourth quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock worth $37,000 after acquiring an additional 130 shares in the last quarter. Finally, UMB Bank n.a. grew its stake in shares of Jazz Pharmaceuticals by 70.9% during the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock worth $38,000 after acquiring an additional 129 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on JAZZ. Morgan Stanley reiterated an “overweight” rating and issued a $183.00 target price (up from $175.00) on shares of Jazz Pharmaceuticals in a research note on Friday, March 7th. JPMorgan Chase & Co. upped their target price on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. HC Wainwright lifted their price target on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a “buy” rating in a research report on Monday, March 10th. Needham & Company LLC reissued a “buy” rating and issued a $210.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, March 5th. Finally, Royal Bank of Canada decreased their target price on Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating for the company in a report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $187.71.

Jazz Pharmaceuticals Stock Down 8.9 %

Shares of NASDAQ JAZZ opened at $110.04 on Friday. The firm has a market cap of $6.68 billion, a price-to-earnings ratio of 15.50, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44. The company’s 50-day simple moving average is $132.27 and its 200-day simple moving average is $122.91. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $148.06.

Insider Activity at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,500 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $122.31, for a total value of $183,465.00. Following the transaction, the chief executive officer now owns 439,744 shares in the company, valued at $53,785,088.64. This trade represents a 0.34 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Neena M. Patil sold 3,800 shares of the business’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $144.87, for a total value of $550,506.00. Following the sale, the executive vice president now owns 33,318 shares of the company’s stock, valued at $4,826,778.66. The trade was a 10.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 28,736 shares of company stock valued at $4,023,305. 4.20% of the stock is owned by corporate insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.